Apple appeal

Apple files appeal after Biden admin allows U.S. ban on watch imports, US-led Red Sea task force in trouble as countries hesitate to join, home prices extend records- rising ninth straight month, Tesla to roll out revamped Model Y, and Israel grants Intel $3.2B for new $25B chip plant…

Author

Market Briefing
December 27, 2023

☕️ Good morning.

The Fast Five → US-led Red Sea task force in trouble as countries hesitate to join, Apple files appeal after Biden admin allows U.S. ban on watch imports, home prices extend records- rising ninth straight month, Tesla to roll out revamped Model Y, and Israel grants Intel $3.2B for new $25B chip plant…

Your 5-minute briefing for Wednesday:

BEFORE THE OPEN

As of market close 12/26/2023.

MARKETS:

  • Stocks gained, pushing the S&P 500 closer to a record.

  • The S&P 500 rose by 0.42%, Nasdaq by 0.54%, and Dow by 0.43%.

  • The Nasdaq 100 reached an all-time high and record close.

  • S&P 500 nears its all-time high set in January 2022.

  • Wall Street enters the week with positive momentum, coming off an eight-week winning streak.

  • Recent data indicates inflation moving toward the Fed’s target.

  • Intel surges 5.2% after receiving a $3.2 billion grant for a $25 billion plant in Israel.

  • Manchester United climbs 3.4% as British billionaire Jim Ratcliffe buys a quarter of the club.

EARNINGS

The earnings calendar is bare between Christmas and New Year's, picking back up the first week of January with Walgreens Boots Alliance (WBA) among the handful of names reporting.

In the following week (January 8-12), major banks will take the spotlight as the fourth-quarter earnings season begins. Stay tuned for our earnings outlook in next week's briefing.

Full earnings calendar here

TODAY’S HEADLINES

The Galaxy Leader cargo ship is escorted by Houthi boats in the Red Sea. This shipping lane is critical for the global economy, seeing around 12% of global trade pass through the strait every year.

Apple asked the Federal Circuit to pause the ban until U.S. Customs decides whether redesigned versions of its watches infringe Masimo’s patents, and to put the ban on hold while the court considers the request. Decision due on Jan. 12.

  • US holiday retail sales grow 3.1%, down from prior year (more)

  • Global stocks edge up, dollar holds near 5-month low (more)

  • Asian stocks rise with year-end cheer, rate cuts in sight (more)

  • US home prices extend records, rising for a ninth straight month (more)

  • US buys 3 million barrels of oil for strategic reserve (more)

  • Big oil enters 2024 strengthened by U.S. industry consolidation (more)

  • Red Sea return will be decided today by shipping group Hapag-Lloyd (more)

  • New IRS tax brackets take effect in 2024, meaning your paycheck could be bigger (more)

  • Israel grants Intel $3.2 billion for new $25 billion chip plant (more)

  • Apple’s iPhone design chief enlisted by Jony Ive, Sam Altman to work on AI devices (more)

  • Tesla to roll out revamped Model Y from Shanghai plant (more)

  • EVs expected to get cheaper in 2024 with ‘more incentives, more discounting’ (more)

  • MicroStrategy’s bitcoin bet produces over 300% gain for investors in 2023 (more)

  • CBS, Paramount owner National Amusements says it was hacked (more)

  • Microsoft Copilot is now available as a ChatGPT-like app on Android (more)

TOGETHER WITH IBD’s MARKETSMITH

The most powerful platform available.

Some call it the ‘affordable’ Bloomberg Terminal. Why?

Because with IBD’s MarketSmith, you'll have access to the same resources and insights as a professional stock market analyst, but at a fraction of the cost. MarketSmith also allows you to streamline your research by consolidating all of the information you need into a single window.

Get smarter trade ideas, analyze them quickly and see when to buy and sell, all in one platform.

🔥 MarketBriefing Exclusive → Get 6-Weeks now for just $49.95 (that’s HALF-OFF the regular price for MB readers!) — so if you’ve ever wanted to give MarketSmith a try, now’s your chance! (limited-time offer)

DEALFLOW

M & A | INVESTMENTS

  • Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push (more)

  • AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal (more)

  • Stonepeak Partners invests in breakdown coverage firm AA (more)

  • Shiseido buys Dr. Dennis Gross Skincare (more)

  • Leonard Green acquires TenCate Grass from Crestview (more)

  • Dunes Point Forms Roofing Services Solutions, Acquires Noland’s Roofing (more)

OTHER

  • Yandex's restructuring deal expected to be delayed to next year (more)

  • India's Infosys falls after $1.5 billion AI deal termination (more)

Was this briefing forwarded to you? Sign Up Here

CRYPTO

  • Grayscale Chair Silbert resigns while SEC mulls Bitcoin ETF (more)

  • Metis surges 50% as ecosystem erojects Eye $360M in grant rewards (more)

  • Spot Bitcoin ETF approval may be coming in January, experts say (more)

  • Hackers stole $2 billion in crypto in 2023, data shows (more)

  • Who won crypto in 2023? The CoinDesk market index broken down in 6 charts (more)

BULLISH BITES

🍺 Tastemaker: The 11 best beers of the year, chosen by a guy who tasted 879.

📊 Forecast: 9 things that will define the economy in 2024.

😎 Retro cool: How McDonald’s used nostalgia and streetwear to become cool again.

🙀 Year in memes: The internet moments that defined 2023.

🔥 Exclusive: Get smarter trade ideas, analyze them quickly and see when to buy and sell — all in one platform. IBD’s MarketSmith give you access to the same resources and insights as a professional stock market analyst, but at a fraction of the cost. Try 6-Weeks now for just $49.95 (limited time)

DAILY SHARES

Know someone who would enjoy this?

Keep the curation going! Buy the team a coffee ☕️

Have a comment or suggestion? We’d love to hear it!
💌 Send us a message

Disclaimer: MarketBriefing is a news publisher. All statements and expressions herein are the sole opinions of the authors or paid advertisers. The information, tools, and material presented are provided for informational purposes only, are not financial advice, and are not to be used or considered as an offer to buy or sell securities; and the publisher does not guarantee their accuracy or reliability. Please conduct your own research and consult an independent financial adviser before making any investments. Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein. Assets mentioned may be owned by members of the MarketBriefing team2/26

Reply

or to participate.